When entering the site and if cookies are prevented from being saved, a message must be displayed
in a popup message box informing the user that their local browser settings are preventing
cookies from being saved and that cookies are required for the site to work. Exact text
to be provided for UAT. On OK click of the message, the user should be redirected to
the global landing page (currently ssga.com).
Coronavirus: A Human Crisis That Should Trigger Chinese Policy Put
While the full impact of the virus remains unclear, it will likely force China to maintain a degree of policy support into the second half of 2020 and possibly beyond.
The novel coronavirus (2019-nCoV) is still in the early phase of accelerating infection rates and, sadly, increasing death rates. Our thoughts are with all those affected by the virus. While much is still unknown, authorities have responded within China, across the globe and in international cooperation. Thus, we have faith that ultimately the outbreak will be contained.
As global investors, we apply a macroeconomic lens to our assessment. Although the nCoV outbreak will almost certainly knock China’s quarterly economic output, the medium- and long-term view could be much less negative.
One risk going into 2020 was the possibility that the Chinese government would reverse course and cut, if not eliminate, its stimulus programs. It is now highly unlikely that we will see a sudden stop to the monetary, fiscal and regulatory stimulus that has helped drive the Chinese recovery since mid-2019.
The importance of public health in China has materially raised the bar for the central, provincial and local governments to effectively manage the acute effects of the epidemic. While laws technically hold the local government accountable, President Xi and the central government exercise centralised power and we expect them to mobilise government resources to limit the economic fallout.
Figure 1: Chinese Fiscal and Monetary Policy Settings Have Been One Directional
Source: State Street Global Advisors Global Macro Policy, Macrobond, IMF, as of 31 January 2020.
In terms of economic impact, nCoV will likely cause Chinese economic growth to drop significantly from 6% during Q1 2020, requiring the Chinese authorities to revisit their plans for ending their stimulus actions. In 2019, fiscal easing was roughly equal to 2% of GDP, with another 0.5% slated for 2020. Along with the Chinese central bank’s monetary policy actions — lowering lending rates and reserve requirements (down 2%) for banks — this combined fiscal-monetary stimulus has helped stabilise Chinese growth and the global recovery.
The phase one US-China trade deal was going to be the trigger to cut back on stimulus, but nCoV makes that prospect unlikely. Instead, we can expect policy support continuing into the second half of 2020 and possibly beyond. Together with the cyclical recovery post epidemic, this means China could well be a growth driver over the whole year, compensating for its role as a source of slowdown in Q1 2020 (assuming the virus effect reverses within two to three months). In the long term, as Figure 1 indicates, this episode reaffirms the “policy put” that has guided Chinese actions for the past decade.
Virus-induced asset price moves are likely to correct once the growth rate of infections slows down. Thereafter, Chinese policy support should provide a tailwind for global equities as well as the renminbi, with positive knock-on effects for other emerging market currencies.
ETFs trade like stocks, are subject to investment risk, fluctuate in market value and may trade at prices above or below the ETFs net asset value. Brokerage commissions and ETF expenses will reduce returns.
SSGA SPDR ETFS MAY NOT BE AVAILABLE OR SUITABLE FOR YOU. THE VIEWS EXPRESSED/INFORMATION IN THIS SITE DO NOT CONSTITUTE INVESTMENT ADVICE, FINANCIAL, LEGAL, REGULATORY, ACCOUNTING OR TAX ADVICE. INDEPENDENT ADVICE SHOULD BE SOUGHT IN CASES OF DOUBT. NEITHER THE INFORMATION NOR ANY OPINION CONTAINED ON THIS SITE CONSTITUTES A SOLICITATION OR OFFER TO BUY OR SELL SHARES OF THE FUNDS OR ANY OTHER FINANCIAL INSTRUMENT.
Standard & Poor's®, S&P® and SPDR® are registered trademarks of Standard & Poor's Financial Services LLC (S&P); Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC (Dow Jones); and these trademarks have been licensed for use by S&P Dow Jones Indices LLC (SPDJI) and sublicensed for certain purposes by State Street Corporation. State Street Corporation's financial products are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates and third party licensors and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability in relation thereto, including for any errors, omissions, or interruptions of any index.
SPDR ETFs may be offered and sold only in those jurisdictions where authorised, in compliance with applicable regulations.
Information related to Mexico
This information does not constitute and is not intended to constitute marketing or an offer of securities and accordingly should not be construed as such. The Funds referenced herein have not been, and will not be, registered under the Mexican Securities Market Law (Ley del Mercado de Valores) and may not be publicly offered or sold in the United Mexican States. Disclosure documentation related to any of the aforementioned Funds may not be distributed publicly in Mexico and shares of the Funds may not be traded in Mexico.
UCITS SPDR ETFs
SPDR ETFs Europe I Plc and SSGA SPDR ETFs Europe II Plc issue SPDR ETFs, and are an open-ended investment company with variable capital having segregated liability between its sub-funds. The Company is organised as an Undertaking for Collective Investments in Transferable Securities (UCITS) under the laws of Ireland and authorised as a UCITS by the Central Bank of Ireland.
This website is directed at Qualified Investors only, as defined by Article 10(3) lit. a and b. of the Swiss Act on Collective Investment Schemes (CISA). Certain funds may not be registered for public distribution with the Swiss Financial Market Supervisory Authority (FINMA), which acts as supervisory authority in investment fund matters, and such funds might not qualify as foreign Collective Investment Schemes under Article 120 of the Collective Investment Schemes Act. Accordingly, the shares of those funds may only be offered to Qualified Investors and not be offered or solicited to any other investor in or from Switzerland, unless they are placed without public solicitation as such term is defined by the Swiss regulations and/or FINMA from time to time The prospectus, the articles of incorporation, the Key Investor Information Document (KIID) as well as the latest annual and semi-annual reports may be obtained free of charge from the Swiss Representative and Paying Agent, State Street Bank International GmbH, Munich, Zurich Branch, Beethovenstrasse 19, 8027 Zurich, or at www.spdrs.com, as well as from the main distributor in Switzerland, State Street Global Advisors AG (“SSGA AG”), Beethovenstrasse 19, 8027 Zurich. For additional documentation regarding those funds not registered for public sale, please contact SSGA AG.
You should obtain and read the SPDR prospectus and relevant Key Investor Information Document (KIID) prior to investing, which may be obtained by clicking here. These include further details relating to the SPDR funds, including information relating to costs, risks and where the funds are authorised for sale.
US SPDR ETFs
The distribution of interests of U.S. SPDR ETFs in Switzerland will be exclusively made to, and directed at, qualified investors (the "Qualified Investors"), as defined in the Swiss Collective Investment Schemes Act of 23 June 2006, as amended ("CISA") and its implementing ordinance. Accordingly, U.S. SPDR ETFs are not registered with the Swiss Financial Market Supervisory Authority ("FINMA"). The legal documents of the U.S. SPDR ETFs can be obtained free of charge from Swiss Representative & Swiss Paying Agent State Street Bank International GmbH Beethovenstrasse 19 8027 Zurich, Switzerland Tel: +41 44 560 5000.
Before investing, consider the funds' investment objectives, risks, charges and expenses. To obtain a prospectus which contains this and other information, download a prospectus here, or talk to your financial advisor. Read it carefully before investing.